Biological and Health Data: Ethical Issues Ethical Data: Health and Biological Use of Is Data Indispensable

Total Page:16

File Type:pdf, Size:1020Kb

Biological and Health Data: Ethical Issues Ethical Data: Health and Biological Use of Is Data Indispensable The collection, linking and use of data in biomedical research and health care: ethical issues Nuffield Council on Bioethics Professor Jonathan Montgomery (Chair) Professor Simon Caney Professor Bobbie Farsides* Professor Peter Furness Professor Ann Gallagher Professor Robin Gill Dr Andy Greenfield Professor Erica Haimes Professor Julian Hughes Sir Roland Jackson Professor Graeme Laurie David K Lawrence Professor Tim Lewens Professor Ottoline Leyser (Deputy Chair) Professor Anneke Lucassen Professor Martin Richards** Dr Tom Shakespeare Dr Geoff Watts Professor Robin A Weiss Professor Heather Widdows Adam Wishart Dr Paquita de Zulueta * co-opted member of the Council while chairing the Working Party on Children and Clinical Research ** co-opted member of the Council while chairing the Working Party on Health and Biological Data: Ethical Issues iii Secretariat Hugh Whittall (Director) Ranveig Svenning Berg Peter Mills Tom Finnegan (until January 2014) Katharine Wright Kate Harvey Catherine Joynson Laura Medhurst Sarah Walker-Robson Carol Perkins Seil Collins Bettina Schmietow (from March 2014) Anna Wilkinson The terms of reference of the Council are: 1. to identify and define ethical questions raised by recent advances in biological and medical research in order to respond to, and to anticipate, public concern; 2. to make arrangements for examining and reporting on such questions with a view to promoting public understanding and discussion; this may lead, where needed, to the formulation of new guidelines by the appropriate regulatory or other body; 3. in the light of the outcome of its work, to publish reports; and to make representations, as the Council may judge appropriate. The Nuffield Council on Bioethics is funded jointly by the Medical Research Council, the Nuffield Foundation, and the Wellcome Trust iv Acknowledgments The Council would like to thank the Working Party for the generous contribution of their time, knowledge and expertise to this project. We should also like to express our thanks to the large number of people, individually and from within institutions and other organisations, who responded to the open consultation that informed the development of the Working Party’s understanding of and approach to the issues addressed in this report. As well as these, we are grateful to the knowledgeable contributors who attended our four ‘fact-finding’ meetings. A list of these people may be found at Appendix 2. The Working Party commissioned two independent reports to assist their deliberations, which are published on the Council’s website alongside this report. The first, commissioned jointly with the Expert Advisory Group on Data Access (EAGDA), explored evidence of the harms associated with misuse of data and the second the relationship between public and private sectors in the use of data in biomedical innovation. We would like to thank the authors of these reports, Professor Graeme Laurie, Ms Leslie Stevens, Dr Kerina H Jones and Dr Christine Dobbs (for the first report) and Professor Paul Martin and Dr Gregory Hollin (for the second). We should also like to thank the members and secretariat of EAGDA for their assistance in commissioning the first independent report and for giving us the opportunity to present and discuss with them the direction of our research at a very early stage. We are also greatly appreciative of the value added to the report by the dozen external reviewers, representing a range of professional backgrounds and academic disciplines, who are listed in Appendix 2. In addition to these, members of the Council, Secretariat and Working Party also benefitted from discussions and correspondence with a number of other individuals at different stages of the project, including Professor Dame Fiona Caldicott, Dr Alan Hassey, Dr William Lowrance, Katherine Littler, Dr Natalie Banner, Dr Alfred Z Spector, Dr John Parkinson, Dr Mark J Taylor, Tim Kelsey, Kingsley Manning, Dr Stephen Pavis, Laura Riley and Adrienne Hunt. We also extend our thanks to Dr Anna Wilkinson of the Nuffield Council Secretariat for her careful proofreading and to Clare Wenham and Tom Burton for additional research and assistance. Finally, we should like to acknowledge the contribution of two members of the original Working Party who, for supervening reasons, were unable to see the report through to completion: Lynn Molloy and Peter Singleton. While the Members of the Working Party listed below take responsibility for the final form of the report, we are very grateful for the valuable contribution of those colleagues to the deliberations. v Foreword The germ of this report might, perhaps, be found in discussions leading to the Council's annual 'forward look' meeting in May 2011. Some time in 2010, with typical foresight and perspicacity, the Council identified a bundle of emerging issues to do with the application of information technology and data science to health records and biological information that had the potential to generate substantial public hopes and concerns. The discussion in May 2011 persuaded the Council that significant and under-explored ethical questions were at stake and that a Council report could offer a useful and timely contribution to debate. I doubt that many of those who, like me, attended the Council's initial scoping workshop in February 2012 would have predicted the shape this report would take or could have imagined just how wide-ranging, complex and passionate the debate would be. Recalling that the project began life under the rubric 'Genomics, Health Records, Database Linkage and Privacy' may shed light on the some of the preoccupations underlying the report that resurfaced repeatedly as it emerged. But when the Working Party set to work in March 2013, with the tide of enthusiasm for 'big data' reaching a high water mark, it seemed that the issues we had to consider were much more general than the use of particular 'kinds' of data or the linking of particular 'kinds' of records. This was confirmed when we began to gather evidence at a number of fact-finding meetings. It was further confirmed by the extraordinary richness of responses to our open consultation. Our task was complicated by the fact that we built on shifting sands. The negotiations around the new European Data Protection Regulation, the well-publicised vicissitudes of the 'care.data' programme and the expectations built around the '100,000 Genomes' project: all these unfolded during our deliberations and remain largely unresolved as we go to press. Although the report addresses these and other examples explicitly, and will no doubt be read differently in the light of further developments, the reader should remember that our principal concerns are moral questions, not contingent questions of law and practice. We have tried to produce a report that adds insight to these but is not diminished by the fact that they may unfold in one way rather than another. We intend and expect, in other words, that readers will continue to find value in our report as initiatives, methodologies, and indeed laws, come and go. Some of the matters that we have had to address – the challenging complexity of health service and research practices, the technical sophistication of data science, for example – were new to many of us and we relied heavily on our colleagues' expertise to bring these unfamiliar concepts into our common grasp. Nevertheless, we could not have reached our objective without the contribution of every member of the Working Party to our deliberations, since each brought a perspective that at times enriched, at others challenged, and often enriched through challenging, the understanding that developed among us. I should here express my gratitude to those colleagues for their hard work and commitment to our objective, and, though we have had some robust debates, for demonstrating a belief in the centripetal potential to produce something of value over the centrifugal force of our differences. Although, for purely contingent reasons, not all of the original Working Party were able to see the project to completion, the imprint of earlier contributions remains on the final document. As a group we are deeply indebted to the Nuffield Council and especially to the subgroup of Council members who reviewed and commented on our output at various stages of the project for their intellectual engagement, wise counsel and moral support throughout. Beyond these we have benefitted considerably from the contributions of numerous others, among them those who responded to our open consultation. Though we vii have not engaged with specific responses explicitly in the report, these have been immensely valuable in informing our thinking, providing a common wealth of knowledge and questions for a diverse working party such as ours to draw on, to discuss and to pursue. We benefitted greatly from the contributions of those who attended our early fact finding meetings, who gave generously of their considerable knowledge and patiently addressed our questions, and of the authors of two independent commissioned reports. Our initial drafts were improved immeasurably thanks to our external reviewers who saw an early draft of this document and commented more in the spirit of collaborators than critics. Though we have not been able to reflect the totality of their advice in a single document, it has enriched and informed the report beyond anything that we might otherwise have achieved; any shortcomings that remain are, of course, our responsibility rather than theirs. Finally, I should thank the members of the Nuffield Council Secretariat who supported our work. Peter Mills, not only organised the whole project, but also undertook the lengthy and arduous task of drafting and editing the report. Without his expertise, patience, and his dedication beyond the call of duty, our work would not have reached a successful conclusion. Peter was ably supported by our research officers, Tom Finnegan (to the end of 2013) and Bettina Schmietow (from March 2014) who also deserve our gratitude.
Recommended publications
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • Faqs on Applying and Accessing UK Biobank Data
    FAQs on applying and accessing UK Biobank data This document contains answers to FAQs from researchers. Please read our UK Biobank Access Policy and Procedures before registering via the UK Biobank Access Management System (AMS). For assistance you can send us a Message via AMS after you have signed up. For queries pre-registration you can email [email protected]. Registration What do I do if I am affiliated with more than one institute? You can add all your current affiliations to a single registration in AMS, listing your personal institute email address for each of them. Who can register for access to the UK Biobank Resource? The Resource is available to all bona fide researchers for all types of health-related research which is in the public interest. What is the cost of Registration? There is no cost to register. I am trying to register but the system will not let me progress. What should I do? If the mandatory fields have been completed please contact the Access Management Team for assistance. Can I register on behalf of someone else? No. The email address used to register must be your personal institute email address. I have submitted my Registration. What happens next? We aim to review all registrations within 10 working days, but this may be longer if additional information is required. My account is locked, what do I do? Follow the process for “What happens if I forget my password?” below. What happens if I forget my password? Click the ‘Forgot your password?’ link on the AMS Log in Page.
    [Show full text]
  • What Does It Mean to Take an Ethics+ Approach to Global Biobank Governance?
    Edinburgh Research Explorer What does it mean to take an ethics+ approach to global biobank governance? Citation for published version: Laurie, G 2017, 'What does it mean to take an ethics+ approach to global biobank governance?', Asian Bioethics Review, vol. 9, no. 4, pp. 285-300. https://doi.org/10.1007/s41649-017-0030-z Digital Object Identifier (DOI): 10.1007/s41649-017-0030-z Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Asian Bioethics Review Publisher Rights Statement: This is a post-peer-review, pre-copyedit version of an article published in Asian Bioethics Review. The final authenticated version is available online at: https://link.springer.com/article/10.1007/s41649-017-0030-z General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 01. Oct. 2021 What Does It Mean to Take an Ethics+ Approach to Global Biobank Governance? Graeme Laurie School of Law, University of Edinburgh Abstract: This article re-examines and fundamentally re-assesses the symbiotic relationship between law and ethics in the governance and regulation of biobanks as a global phenomenon.
    [Show full text]
  • Property Redux. Ownership of Human Tissue and the Governance of Post-Genomic Research Biobanks
    PhD degree in “Foundations and Ethics of the Life Sciences” European School of Molecular Medicine (SEMM) and University of Milan Faculty of Medicine Settore disciplinare: M-FIL/02 PROPERTY REDUX. OWNERSHIP OF HUMAN TISSUE AND THE GOVERNANCE OF POST-GENOMIC RESEARCH BIOBANKS Bettina Schmietow IFOM-IEO Campus, Milan Matricola n. R08920 Supervisor: Dr. Matteo Mameli IFOM-IEO Campus, Milan Anno accademico 2012-2013 Abstract Biobank-based genomic research is considered instrumental to realize Personalised Medicine and considerable benefits for diagnosis and therapy of many common complex diseases. It raises manifold ethical and regulatory challenges which are discussed extensively, the main focus being on adaptations of Informed Consent to the emerging research context. This study highlights challenges to the strongly individualistic focus of classical research ethics in confrontation with biobank development. The debate on adequate protections for individual donor-participants tends towards deflationary accounts of participant rights, in which in particular the dimension of potential property in human tissue and genomic information is undervalued. Criticizing the common bioethical and legal stance that there can and should be no property in the human body and its parts, the close conceptual connections between privacy, property and consent underlying the protection of a more substantive version of participant integrity are emphasized. While ultimately the framework of traditional, in particular individual property rights is ill-suited to safeguard participant and public interests in research, property discourse is fundamental to advance discussion on the direction biobank ethics and governance should take by 1) taking serious the reordering of individual, group and societal interests in biobank research, 2) clarifying strength and limits of claims to “autonomy” and 3) refocusing to public or common goods biobank research should provide.
    [Show full text]
  • Select Bibliography
    Select Bibliography (A more detailed Bibliography is available on the The Federation Press website) Aatre, Rajani, and Sharlene Day, ‘Psychological issues in genetic testing for inherited cardiovascular diseases’ (2011) 4 Circulation: Cardiovascular Genetics 87 Abadie, Alberto, and Sebastien Gay, ‘The Impact of Presumed Consent Legislation on Cadaveric Organ Donation: A Cross-Country Study’ (2006) 25(4) Journal of Health Economics 599 Abbing, HDC Roscam, Jan KM Gevers, Ewoud H Hondius and JH Hubben (eds), Health Law, Human Rights and the Bioethics Convention: Essays in Honour of Henriette Abbing (Martinus Nijhoff, Amsterdam, 2005) Abbott, FM, ‘The enduring enigma of TRIPS: A challenge for the world economic system’ (1998) 1 Journal of International Economic Law 497 Abbott, Katherine, et al, ‘Families Looking Back: One Year After Discussion of Withdrawal or Withholding of Life-Sustaining Support (2001) 29(1) Critical Care Medicine 197 Abegunde, Dele O, et al, ‘The Burden and Costs of Chronic Diseases in Low-Income and Middle-Income Countries’ (2007) 370 The Lancet 1929 Abel, Richard, Politics by Other Means: Law in the Struggle Against Apartheid 1980 – 1994 (Routledge, New York and London, 1st ed, 1995) Abrams, Paula, ‘The Bad Mother: Stigma, Abortion and Surrogacy’ (2015) 43 Journal of Law, Medicine and Ethics 179 ACCC, ‘ACCC tackles Homeopathy Plus! Whooping Cough claims’, <http://www.accc.gov.au/content/ index.phtml/itemId/1049609/fromItemId/142> ACMG Board of Directors, ‘ACMG Policy Statement: Updated Recommendations Regarding Analysis
    [Show full text]
  • Ethical Aspects of Human Biobanks Are a Very Fast-Evolving Field
    262 REVIEW ARTICLE doi: 10.3325/cmj.2011.52.262 Ethical aspects of human Danijela Budimir1, Ozren Polašek1, Ana Marušić1,2, biobanks: a systematic review Ivana Kolčić1, Tatijana Zemunik1, Vesna Boraska1, Ana Jerončić1, Mladen Boban1, Harry Campbell3, Igor Rudan1,2,3 1University of Split School of Aim To systematically assess the existing literature on ethi- Medicine, Split, Croatia cal aspects of human biobanks. 2Croatian Centre for Global Health, Method We searched the Web of Science and PubMed University of Split School of databases to find studies addressing ethical problems in Medicine, Split, Croatia biobanks with no limits set (study design, study popula- 3Public Health Sciences, University tion, time period, or language of publication). All identified of Edinburgh, Edinburgh, UK articles published until November 2010 were included. We analyzed the type of published articles, journals publishing them, involvement of countries/institutions, year of pub- lication, and citations received, and qualitatively assessed every article in order to identify ethical issues addressed by the majority of published research on human biobanking. Results Hundred and fifty four studies satisfied our re- view criteria. The studies mainly came from highly devel- oped countries and were all published in the last two de- cades, with over half of them published in 2009 or 2010. They most commonly discussed the informed consent, privacy and identifiability, return of results to participants, importance of public trust, involvement of children, com- mercialization, the role of ethics boards, international data exchange, ownership of samples, and benefit sharing. Conclusions The focus on ethical aspects is strongly pres- ent through the whole biobanking research field.
    [Show full text]
  • The Ethics of Biobanking: Key Issues and Controversies
    Health Care Anal (2011) 19:207–219 DOI 10.1007/s10728-011-0184-x EDITORIAL The Ethics of Biobanking: Key Issues and Controversies Heather Widdows • Sean Cordell Published online: 22 July 2011 Ó Springer Science+Business Media, LLC 2011 Introduction The ethics of biobanking is one of the most controversial issues in current bioethics and public health debates. For some, biobanks offer the possibility of unprecedented advances which will revolutionise research and improve the health of future generations. For others they are worrying repositories of personal information and tissue which will be used without sufficient respect for those from whom they came. Wherever one stands on this spectrum, from an ethics perspective biobanks are revolutionary. Traditional ethical safeguards of informed consent and confidenti- ality, for example, simply don’t work for the governance of biobanks and as a result new ethical structures are required. Thus it is not too great a claim to say that biobanks require a rethinking of our ethical assumptions and frameworks which we have applied generally to other issues in ethics. This special issue is dedicated to addressing these issues from the different perspectives of law, philosophy, medical ethics and sociology. This paper begins with a broad introduction to the ‘ethics of biobanking’ which maps the key challenges and controversies of biobanking ethics; it considers; informed consent (its problems in biobanking and possibilities of participants’ withdrawal), broad consent, the problems of confidentiality, owner- ship, property and comercialisation issues, feedback to participants and the ethics of re-contact. The papers in this special issue were all presented at the eighth international workshop of the Tiss.EU Project on the theme ‘Biobanking: Ethics, Governance and Regulation’, at the University of Birmingham, UK, in June 2010.
    [Show full text]
  • Ethics Guidelines for Human Biomedical Research
    ETHICS GUIDELINES FOR HUMAN BIOMEDICAL RESEARCH BIOETHICS ADVISORY COMMITTEE SINGAPORE June 2015 FOREWORD The Ethics Guidelines for Human Biomedical Research is a timely publication to mark the 15th anniversary of the Bioethics Advisory Committee (BAC). The landscape of the biomedical sciences in Singapore has changed tremendously since the inception of the BAC. When BAC first started in 2000, Singapore did not have a robust system of ethics review for human biomedical research in place. The BAC’s recommendations over the years have contributed to the establishment of a framework of research ethics governance in Singapore. Today, all human biomedical research in public healthcare, tertiary and research institutions are reviewed, and there are ethics governance frameworks in place to ensure that research participants are properly protected. The BAC strives to make recommendations that are aligned with international best practices, but also sensitive to and applicable in our local context. As some of the recommendations that BAC had made were issued more than a decade ago, it is important that these positions are revisited, to ensure their relevance given scientific, regulatory and legal developments. This will facilitate in ensuring that human biomedical research in Singapore continues to be conducted in accordance with ethical standards that are recognised internationally. Ethical pronouncements on what is considered sensitive or unacceptable may change with time as a result of research and technological advances, or in accordance with social or cultural developments. Regular reviews are therefore important to remain in touch with the public’s sentiments and concerns, to ensure that there is adequate regulation for the protection of research participants, and not unduly impede potentially beneficial research.
    [Show full text]
  • The Ethical and Legal Regulation of Human Tissue and Biobank Research Across the 27 European Member States Plus Switzerland
    uman tissue and biobank research is of increasing importance for Katharina Beier, Hunderstanding the causes of widespread diseases and developing Silvia Schnorrer, effective therapies. However, while the success of biobank research depends Nils Hoppe, on the availability of a large number of samples and the consolidation of collections across country borders is very desirable from the perspective Christian Lenk (eds.) of researchers, the legal and ethical requirements for the procurement, storage and use of human tissue samples are rather heterogeneous across The Ethical and different countries. Moreover, the lack of comprehensive supranational Legal Regulation of regulation on human tissue and biobanking can be seen as posing a serious threat to transnational biomedical research. Against this background, it was Human Tissue and one of the aims of the EU-funded Tiss.EU project (“Evaluation of Legislation Biobank Research and Related Guidelines on the Procurement, Storage and Transfer of Human Tissues and Cells in the European Union – an Evidence-Based Impact Analysis”) in Europe to analyse the ethical and legal regulation of human tissue and biobank research across the 27 European Member States plus Switzerland. The Proceedings of the results of nine international workshops and three conferences are gathered in this volume. While the country reports evaluate the implementation of Tiss.EU Project ethical and legal guidelines at a national level, point out their strengths and deficits, and, where required, create an evidence base for the revision of said legislation, the conference reports address more general ethical and legal issues in this field. The volume is completed by a final presentation of project’s results.
    [Show full text]
  • UK BIOBANK ETHICS and GOVERNANCE FRAMEWORK Version 3.0 (October 2007)
    UK BIOBANK ETHICS AND GOVERNANCE FRAMEWORK Version 3.0 (October 2007) UK BIOBANK 3 Purpose and overview 3 Organisation and funding 3 I. RELATIONSHIP WITH PARTICIPANTS 4 A. RECRUITMENT 4 1. General principles 4 2. Selection and approach 4 3. Enrolment 4 B. UNDERSTANDINGS AND CONSENT 5 1. Consent 5 2. Collection of data from health­relevant records 6 3. Provision of health information to participants 6 4. Ongoing engagement with participants and the public 8 5. Expectation of re­contact 8 6. Right to withdraw 9 7. Respect for incapacitated or deceased participants’ wishes 10 8. Expectation of personal financial gain 10 C. CONFIDENTIALITY 10 1. Commitment to maintaining confidentiality 11 2. Anonymisation 11 3. Re­identification 11 4. Security 11 II. RELATIONSHIP WITH RESEARCH USERS 12 A. STEWARDSHIP OF DATA AND SAMPLES 12 B. RESEARCH ACCESS TO DATA AND SAMPLES 12 1. General principles of access 12 2. Decisions on access and use 13 3. Licences for specific uses 13 4. Sharing of data and findings 13 III. RELATIONSHIP WITH SOCIETY 14 A. MANAGEMENT AND ACCOUNTABILITY 14 1. Board of Directors 14 2. Ethics and Governance Council 14 3. Steering Committee and International Scientific Advisory Board 15 B. EXTERNAL GOVERNANCE 15 1. Ethics approval review by relevant ethics committees 15 2. Compliance with Research Governance Frameworks 17 C. BENEFIT SHARING 17 1. Dissemination of knowledge generally 17 2. Intellectual property, income generation and royalties 18 D. TRANSFER OF ASSETS, OR CLOSURE 18 IV. ADOPTION, IMPLEMENTATION AND REVISION 19 A. ADOPTION 19 B. IMPLEMENTATION 19 C. REVISION 19 ANNEX Ethics and Governance Council terms of reference 20 2 UK BIOBANK Purpose and overview UK Biobank aims to build a major resource that can support a diverse range of research intended to improve the prevention, diagnosis, and treatment of illness and the promotion of health throughout society.
    [Show full text]
  • Partnership in UK Biobank
    SYMPOSIUM lthough scientific and commercial excitement Partnership in about genomic biobanks has subsided since A the biotech bust in 2000, they continue to fas- cinate life scientists, bioethicists, and politicians alike. U.K. Biobank: Indeed, these assemblages of personal health infor- mation, human DNA, and heterogeneous capital have become and remain important events in the ethics and A Third Way politics of the life sciences.1 For starters, they continue to reveal and produce the central scientific, technolog- For Genomic ical, and economic paradigms so ascendant in biology today: genome, infotech, and market. Biobanks also illustrate what might be called the new distributive Property? politics of biomedical research. Within those politics, the commodification of persons – or at the very least, David E. Winickoff of their informational representations – has chal- lenged the ontological, ethical, and political under- pinnings of the social contract between researchers and their human research subjects.2 In brief, biobanks are unsettling relations between genes, tissue, medical records, and persons (both individual and collective). But it is also clear that these relations are increasingly being restructured by new rights of control, access, exclusion, and use known as “property,” both material and intellectual. Bioethics scholarship on biobank governance has comparatively ignored property in favor of focusing on consent, Institutional Review Boards (IRBs), and privacy.3 This is both expected and strange. Expected because bioethics as a field has tended to focus on the claims of individuals rather than collectivities, and it has insufficiently theorized the role of capital in research. And strange for two reasons: first, because in a research domain permeated by markets, property entitlement is so obviously constitutive of the ethical order;4 second, because recent disputes around the ownership of medical records, genetic data, and tis- sue samples demonstrate that the now-famous Moore v.
    [Show full text]
  • Market Report Biobank Ethics Committee for Approval of Biobanks
    Market Report South Africa Section Biobank Ethics Committee for Approval of Biobanks The Human Research Ethics Committee (HREC), University of implemented should be in accordance with accountability, the Witwatersrand (WITS), has regulated that all biobanks being transparency and good governance, and within the legal and accessed by researches submitting protocols for review are required ethical framework of South African guidelines for good practice in to undergo a formal approval and registry process through a the conduct of clinical trials in human participants and ICH-GCP, subcommittee of the HREC known as the Biobank Ethics Committee and the WMA Declaration of Helsinki ethical principles for medical (BEC). The committee has been assigned with a mandate to research involving human subjects. review all such research applications for biobank storage, or for The primary objective of the biobank would be to foster research by the registration of a biobank requesting approval for the storage making human biological materials readily available to researchers of human biological material (HBM). The BEC reviews all such for testing, knowledge advancement, scientific development, applications and makes recommendations back to the HREC. The research breakthrough and long-term storage. The biobanking committee has been tasked with development of principles, policies policies and procedures should be in compliance to good clinical and guidelines for the biobanks. laboratory practice, best bio repository guidelines, best cold chain practices,
    [Show full text]